CMS MAHA ELEVATEFree Resource

Supporting MAHA ELEVATE With Transparent Medication Data.

EvidentMeds is a free, citation-backed medication evidence directory with clinical trial funding disclosed, lifestyle alternative evidence ratings, and pharmacogenomics context - built to support the kind of evidence-driven care ELEVATE promotes.

What Is CMS MAHA ELEVATE?

Make America Healthy Again - Evaluating Lifestyle, Education, and Verified Alternative Treatment Efficacy is a CMS initiative funding 30 community health organizations to rigorously test whether structured lifestyle interventions can reduce chronic disease burden. The program launches September 2026.

30 CMS Awardees

Community health organizations testing structured lifestyle interventions alongside evidence-based medication optimization

Evidence-Driven

Programs must demonstrate measurable outcomes, reduced HbA1c, weight loss, medication optimization, improved biomarkers

Pro-Evidence, Not Anti-Medication

ELEVATE is about ensuring every prescription is justified by evidence, and every lifestyle intervention is grounded in data

Evidence Brief Generator

Search for a specific medication or select a condition to generate a data-driven evidence brief. Each brief pulls real cost, efficacy, side effect, and lifestyle alternative data from our directory.

Pre-diabetes / Metabolic Syndrome

Evidence Brief for MAHA ELEVATE Program Design - 4 medications analyzed

Medications - Cost, Efficacy & Lifestyle Alternatives

Monthly Cost$10-20
Top Side EffectsNausea (25%), Diarrhea (28%), Stomach upset / cramping (20%)
Trial FundingUKPDS: UK government funded. DPP: NIH funded. Most major metformin trials are government or non-profit funded, unusual for diabetes drugs.
Lifestyle Alternatives

Low-carb diet: Comparable A1C reduction to metformin

Weight loss (5-10%): -0

Exercise: Improves insulin sensitivity 48-72h per session

Very low-carbohydrate diet (<50g/day) - Strong

Mediterranean diet - Strong

Resistance training (3×/week) - Strong

Monthly Cost$450-550
Top Side EffectsNausea (20%), Diarrhea (15%), Vomiting (10%)
Trial FundingSTEP trials and most published semaglutide research were funded by Novo Nordisk, which reported approximately $38.6B in semaglutide revenue in 2023. L
Lifestyle Alternatives

Ketogenic Diet (<20g net carbs/day): HbA1c -1

Time-Restricted Eating (16:8 or OMAD): Improves fasting insulin, HbA1c, and visceral fat independently of caloric restriction

Resistance Training (3×/week): Increases GLUT4 transporter density in muscle; glucose disposal increases 48%; HbA1c improves independently of weight loss; reduces visceral adipose tissue

Low-carbohydrate diet - Strong

Intermittent fasting (16:8 or 5:2) - Strong

Mediterranean diet - Strong

Monthly Cost$550–650
Top Side EffectsGenital yeast infections (9%), Urinary tract infections (9%), Increased urination / dehydration (12%)
Trial FundingAll major Jardiance outcomes trials were funded and conducted by Boehringer Ingelheim and Eli Lilly. EMPA-REG was a landmark trial that showed cardiov
Lifestyle Alternatives

Ketogenic Diet (<20g net carbs/day): HbA1c reduction 1

Resistance Training (3×/week): Increases GLUT4 transporter density; glucose disposal increased 48%; improvements persist 48–72 hours per session

Time-Restricted Eating (16:8): Improves fasting insulin, HbA1c, and visceral fat independently of caloric restriction

Monthly Cost$550–650
Top Side EffectsGenital mycotic infections (yeast) (7–8%), Urinary tract infections (7%), Increased urination / polyuria (10%)
Trial FundingAll major Farxiga outcome trials were funded by AstraZeneca. The DAPA-CKD trial, which expanded the indication to chronic kidney disease regardless of
Lifestyle Alternatives

Carbohydrate Restriction (<50g/day): Low-carb diets achieve HbA1c reductions of 0

Structured Exercise (Aerobic + Resistance): Regular exercise improves eGFR, reduces proteinuria, and lowers blood pressure 5–10 mmHg, addressing both diabetic and CKD endpoints simultaneously

DASH Diet for Hypertension/CKD: DASH diet reduces systolic BP 8–14 mmHg; in CKD patients, blood pressure control is the single most important factor in slowing progression

Key Studies Referenced

UKPDS (gold standard), DPP, Cochrane meta-analysis · SUSTAIN-1 through SUSTAIN-10, PIONEER, SELECT, STEP program · EMPA-REG OUTCOME (2015), EMPEROR-Reduced (2020), EMPEROR-Preserved (2021) · DECLARE-TIMI 58 (2019), DAPA-HF (2019), DAPA-CKD (2020)

Full medication profiles include clinical trial funding sources, side effect rates, tapering protocols, pharmacogenomics data, and comprehensive alternative evidence ratings.

Browse Directory

Frequently Asked Questions

What is CMS MAHA ELEVATE?

MAHA ELEVATE (Make America Healthy Again, Evaluating Lifestyle, Education, and Verified Alternative Treatment Efficacy) is a CMS initiative funding 30 community health organizations to test whether structured lifestyle interventions can reduce chronic disease burden. The program launches September 2026.

How does EvidentMeds support MAHA ELEVATE?

EvidentMeds provides a free evidence layer that directly aligns with ELEVATE's mission: transparent, citation-backed medication profiles with clinical trial funding disclosed, lifestyle alternative evidence ratings, and pharmacogenomics context. ELEVATE awardees and applicants can use these tools to build evidence-driven program designs and support deprescribing decisions with real data.

Is EvidentMeds anti-medication?

No. EvidentMeds is pro-evidence. Many medications are life-saving and irreplaceable. Our role is to ensure clinicians and patients have transparent access to clinical trial data, funding sources, and lifestyle alternatives, so treatment decisions are informed, not influenced by marketing. We follow the evidence wherever it leads.

How can we partner with EvidentMeds?

We'd love to explore how EvidentMeds can support MAHA ELEVATE awardees and applicants. Contact Solutions 2 Wellness, LLC at info@solutions2wellness.org to start a conversation about how we can help.

Let's Explore How We Can Help

We built EvidentMeds to support evidence-driven care, and MAHA ELEVATE represents exactly that mission. If you'd like to explore how this resource can support ELEVATE awardees or applicants, we'd welcome the conversation.

The Evidence Layer for MAHA ELEVATE.

Explore transparent medication profiles, generate evidence briefs, and reach out when you're ready to connect.